A connection between plasma levels of haptoglobin (Hp) and Alzheimer’s disease (AD) has been shown in several observational studies. It is debatable, nonetheless, how the two are related causally.
Objective:
To establish the causal relationship between Hp and AD using a two-sample Mendelian randomization (MR) study.
Methods:
From the extensive genome-wide association studies and FinnGen dataset, summaries and statistics pertaining to AD were gathered. We investigated the possibility of a causal link between Hp and AD using a two-sample MR study. Inverse variance weighting was used as the primary analytical technique, and it was supported by the joint application of complementary analyses and fixed effects meta-analysis to combine results from various sources.
Results:
Genetically determined Hp was causally associated with AD [odds ratio (OR), 1.05; 95% confidence interval (CI), 1.02 to 1.09; p = 8.96×10–4]; Inverse variance-weighted estimates coming from different data sources were combined in a meta-analysis with consistent findings (OR, 1.03; 95% CI, 1.01 to 1.05; p = 2.00×10–3). The outcomes of the inverse MR analysis showed that AD had no appreciable causal impact on Hp.
Conclusion:
The present MR analysis shows that higher plasma Hp leads to an increased risk of AD. Strategies for plasma Hp testing may open up new doors for the early diagnosis and prevention of AD.
HeppnerFL, RansohoffRM, BecherB (2015) Immune attack: The role of inflammation in Alzheimer disease. Nat Rev Neurosci16, 358–372.
2.
PohankaM (2018) Oxidative stress in Alzheimer disease as a target for therapy. Bratisl Lek Listy119, 535–543.
3.
SadrzadehSM, BozorgmehrJ (2004) Haptoglobin phenotypes in health and disorders. Am J Clin Pathol121 Suppl, S97–S104.
4.
BowmanBH, KuroskyA (1982) Haptoglobin: The evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet12, 189-261, 453–184.
5.
AytonS, JanelidzeS, RobertsB, PalmqvistS, KalinowskiP, DioufI, BelaidiAA, StomrudE, BushAI, HanssonO (2021) Acute phase markers in CSF reveal inflammatory changes in Alzheimer’s disease that intersect with pathology, APOE ɛ4, sex and age. Prog Neurobiol198, 101904.
6.
YerburyJJ, WilsonMR (2010) Extracellular chaperones modulate the effects of Alzheimer’s patient cerebrospinal fluid on Abeta(1-42) toxicity and uptake. Cell Stress Chaperones15, 115–121.
7.
ZhuCJ, JiangGX, ChenJM, ZhouZM, ChengQ (2018) Serum haptoglobin in Chinese patients with Alzheimer’s disease and mild cognitive impairment: A case-control study. Brain Res Bull137, 301–305.
8.
PhilbertSA, XuJ, UnwinRD, DowseyAW, CooperGJS (2021) Widespread severe cerebral elevations of haptoglobin and haemopexin in sporadic Alzheimer’s disease: Evidence for a pervasive microvasculopathy. Biochem Biophys Res Commun555, 89–94.
LawlorDA, HarbordRM, SterneJA, TimpsonN, Davey SmithG (2008) Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat Med27, 1133–1163.
11.
BurgessS, ButterworthA, ThompsonSG (2013) Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol37, 658–665.
12.
Davey SmithG, HemaniG (2014) Mendelian randomization: Genetic anchors for causal inference in epidemiological studies. Hum Mol Genet23, R89–98.
13.
BurgessS, ScottRA, TimpsonNJ, Davey SmithG, ThompsonSG (2015) Using published data in Mendelian randomization: A blueprint for efficient identification of causal risk factors. Eur J Epidemiol30, 543–552.
14.
SkrivankovaVW, RichmondRC, WoolfBAR, YarmolinskyJ, DaviesNM, SwansonSA, VanderWeeleTJ, HigginsJPT, TimpsonNJ, DimouN, LangenbergC, GolubRM, LoderEW, GalloV, Tybjaerg-HansenA, Davey SmithG, EggerM, RichardsJB (2021) Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: The STROBE-MR statement. JAMA326, 1614–1621.
15.
SuhreK, ArnoldM, BhagwatAM, CottonRJ, EngelkeR, RafflerJ, SarwathH, TharejaG, WahlA, DeLisleRK, GoldL, PezerM, LaucG, El-Din SelimMA, Mook-KanamoriDO, Al-DousEK, MohamoudYA, MalekJ, StrauchK, GrallertH, PetersA, KastenmüllerG, GiegerC, GraumannJ (2017) Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun8, 14357.
16.
ZhuZ, ZhengZ, ZhangF, WuY, TrzaskowskiM, MaierR, RobinsonMR, McGrathJJ, VisscherPM, WrayNR, YangJ (2018) Causal associations between risk factors and common diseases inferred from GWAS summary data. Nat Commun9, 224.
17.
KamatMA, BlackshawJA, YoungR, SurendranP, BurgessS, DaneshJ, ButterworthAS, StaleyJR (2019) PhenoScanner V2: An expanded tool for searching human genotype-phenotype associations. Bioinformatics35, 4851–4853.
18.
BennM, NordestgaardBG, Frikke-SchmidtR, Tybjærg-HansenA (2017) Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study. BMJ357, j1648.
19.
MengL, WangZ, JiHF, ShenL (2022) Causal association evaluation of diabetes with Alzheimer’s disease and genetic analysis of antidiabetic drugs against Alzheimer’s disease. Cell Biosci12, 28.
20.
TwarowskiB, HerbetM (2023) Inflammatory processes in Alzheimer’s disease-pathomechanism, diagnosis and treatment: A review. Int J Mol Sci24, 6518.
DeCarliC (2021) The link between blood pressure and Alzheimer’s disease. Lancet Neurol20, 878–879.
23.
BuchmanAS, WilsonRS, BieniasJL, ShahRC, EvansDA, BennettDA (2005) Change in body mass index and risk of incident Alzheimer disease. Neurology65, 892–897.
24.
ShimH, ChasmanDI, SmithJD, MoraS, RidkerPM, NickersonDA, KraussRM, StephensM (2015) A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians. PLoS One10, e0120758.
25.
BurgessS, ThompsonSG (2011) Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol40, 755–764.
26.
YangM, YuH, XuK, XieJ, ZhengH, FengR, WangJ, XuP (2023) No evidence of a genetic causal relationship between ankylosing spondylitis and iron homeostasis: A two-sample Mendelian randomization study. Front Nutr10, 1047640.
27.
KunkleBW, Grenier-BoleyB, SimsR, BisJC, DamotteV, NajAC, BolandA, VronskayaM, van der LeeSJ, Amlie-WolfA, et al. (2019) Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet51, 414–430.
28.
HemaniG, ZhengJ, ElsworthB, WadeKH, HaberlandV, BairdD, LaurinC, BurgessS, BowdenJ, LangdonR, TanVY, YarmolinskyJ, ShihabHA, TimpsonNJ, EvansDM, ReltonC, MartinRM, Davey SmithG, GauntTR, HaycockPC (2018) The MR-Base platform supports systematic causal inference across the human phenome. Elife7, e34408.
29.
YavorskaOO, BurgessS (2017) MendelianRandomization: An R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol46, 1734–1739.
30.
VerbanckM, ChenCY, NealeB, DoR (2018) Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet50, 693–698.
31.
BurgessS, ThompsonSG (2017) Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol32, 377–389.
32.
BowdenJ, Davey SmithG, HaycockPC, BurgessS (2016) Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol40, 304–314.
33.
LiC, NiuM, GuoZ, LiuP, ZhengY, LiuD, YangS, WangW, LiY, HouH (2022) A mild causal relationship between tea consumption and obesity in general population: A two-sample Mendelian randomization study. Front Genet13, 795049.
BowdenJ, Davey SmithG, BurgessS (2015) Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. Int J Epidemiol44, 512–525.
36.
GrecoMF, MinelliC, SheehanNA, ThompsonJR (2015) Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med34, 2926–2940.
37.
BowdenJ, Del GrecoMF, MinelliC, Davey SmithG, SheehanN, ThompsonJ (2017) A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med36, 1783–1802.
38.
HemaniG, TillingK, Davey SmithG (2017) Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet13, e1007081.
39.
BrionMJ, ShakhbazovK, VisscherPM (2013) Calculating statistical power in Mendelian randomization studies. Int J Epidemiol42, 1497–1501.
40.
HugoJ, GanguliM (2014) Dementia and cognitive impairment: Epidemiology, diagnosis, and treatment. Clin Geriatr Med30, 421–442.
41.
LeclercJL, LiC, JeanS, LampertAS, AmadorCL, DillerMA, TolosanoE, DoréS (2019) Temporal and age-dependent effects of haptoglobin deletion on intracerebral hemorrhage-induced brain damage and neurobehavioral outcomes. Exp Neurol317, 22–33.
42.
ZhangR, BarkerL, PinchevD, MarshallJ, RasamoelisoloM, SmithC, KupchakP, KireevaI, IngrattaL, JackowskiG (2004) Mining biomarkers in human sera using proteomic tools. Proteomics4, 244–256.
43.
WangYR, YangYH, LuCY, ChenSH (2015) Utilization of magnetic nanobeads for analyzing haptoglobin in human plasma as a marker of Alzheimer’s disease by capillary electrophoretic immunoassay with laser-induced fluorescence detection. Anal Chim Acta865, 76–82.
SmithGD, EbrahimS (2003) ‘Mendelian randomization’: Can genetic epidemiology contribute to understanding environmental determinants of disease?Int J Epidemiol32, 1–22.
46.
VoetS, SrinivasanS, LamkanfiM, van LooG (2019) Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Mol Med11, e10248.
47.
ArgüellesS, VeneroJL, García-RodriguezS, Tomas-CamardielM, AyalaA, CanoJ, MachadoA (2010) Use of haptoglobin and transthyretin as potential biomarkers for the preclinical diagnosis of Parkinson’s disease. Neurochem Int57, 227–234.
48.
HuangYC, WuYR, TsengMY, ChenYC, HsiehSY, ChenCM (2011) Increased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with Huntington’s disease. PLoS One6, e15809.
49.
WanC, LaY, ZhuH, YangY, JiangL, ChenY, FengG, LiH, SangH, HaoX, ZhangG, HeL (2007) Abnormal changes of plasma acute phase proteins in schizophrenia and the relation between schizophrenia and haptoglobin (Hp) gene. Amino Acids32, 101–108.
50.
YerburyJJ, RybchynMS, Easterbrook-SmithSB, HenriquesC, WilsonMR (2005) The acute phase protein haptoglobin is a mammalian extracellular chaperone with an action similar to clusterin. Biochemistry44, 10914–10925.
SpagnuoloMS, MarescaB, La MarcaV, CarrizzoA, VeronesiC, CupidiC, PiccoliT, MalettaRG, BruniAC, AbresciaP, CiglianoL (2014) Haptoglobin interacts with apolipoprotein E and beta-amyloid and influences their crosstalk. ACS Chem Neurosci5, 837–847.
53.
PanM, WangP, ZhengC, ZhangH, LinS, ShaoB, ZhugeQ, JinK (2017) Aging systemic milieu impairs outcome after ischemic stroke in rats. Aging Dis8, 519–530.
54.
DingJ, KopchickJJ (2011) Plasma biomarkers of mouse aging. Age (Dordr)33, 291–307.
